{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:44:43Z","timestamp":1781768683973,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003803","name":"The University of Hong Kong","doi-asserted-by":"publisher","award":["103034014"],"award-info":[{"award-number":["103034014"]}],"id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003803","name":"The University of Hong Kong","doi-asserted-by":"publisher","award":["200010837"],"award-info":[{"award-number":["200010837"]}],"id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vaccine.2025.127625","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T09:13:25Z","timestamp":1755854005000},"page":"127625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong"],"prefix":"10.1016","volume":"63","author":[{"given":"Dijing","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bishai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Wing Tak","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Ann","family":"Gr\u00e9pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Dan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Ka Ki","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Chi Wai","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2025.127625_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30158-X","article-title":"MSM in England to be offered free HPV vaccination","volume":"19","author":"Kirby","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.vaccine.2025.127625_bb0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1473-3099(18)30802-8","article-title":"Gender-neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness","volume":"19","author":"Lechner","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.2017.74.9291","article-title":"Anal cancer risk among people with HIV infection in the United States","volume":"36","author":"Col\u00f3n-L\u00f3pez","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0020","article-title":"Uptake and service preferences of human papillomavirus vaccination in men who have sex with men","volume":"21","author":"Zhang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"issue":"9","key":"10.1016\/j.vaccine.2025.127625_bb0030","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1016\/S2214-109X(23)00305-4","article-title":"Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis","volume":"11","author":"Bruni","year":"2023","journal-title":"Lancet Glob. Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/infdis\/jiq016","article-title":"Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men","volume":"203","author":"Goldstone","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.vaccine.2025.127625_bb0040","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.vaccine.2025.127625_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-021-00328-x","article-title":"The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong","volume":"19","author":"Cheung","year":"2021","journal-title":"Cost Effective Resource Allocation"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127625_bb0050","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2184605","article-title":"Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong","volume":"19","author":"Cheung","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"S10","key":"10.1016\/j.vaccine.2025.127625_bb0055","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/cncr.23744","article-title":"Understanding the burden of human papillomavirus-associated anal cancers in the US","volume":"113","author":"Joseph","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127625_bb0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1016280411280","article-title":"A study of the STD\/AIDS related attitudes and behaviors of men who have sex with men in Hong Kong","volume":"31","author":"Lau","year":"2002","journal-title":"Arch. Sex. Behav."},{"key":"10.1016\/j.vaccine.2025.127625_bb0065","series-title":"PRiSM \u2013 HIV Prevalence and Risk Behavioural Survey of Men who have sex with men in Hong Kong 2017","author":"Centre for Health Protection, D.o.H","year":"2018"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0070","article-title":"Community-based surveys for determining the prevalence of HIV, chlamydia, and gonorrhoea in men having sex with men in Hong Kong","volume":"2013","author":"Wong","year":"2013","journal-title":"J. Sex. Transm. Dis."},{"key":"10.1016\/j.vaccine.2025.127625_bb0075","series-title":"An overview of HIV\/AIDS situation of Men who have sex with men (MSM) in Hong Kong: Factsheet for community stakeholders' consultation meeting (CCM) 2021","author":"Department of Health, H.K","year":"2021"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127625_bb0080","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300194","article-title":"Immunogenicity of 2 or 3 doses of 9vHPV vaccine in US female individuals 15 to 26 years of age","volume":"3","author":"Berenson","year":"2024","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.vaccine.2025.127625_bb0085","first-page":"135","article-title":"Australia to be first country to vaccinate boys against HPV","volume":"367","author":"Brower","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"42","key":"10.1016\/j.vaccine.2025.127625_bb0090","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127625_bb0095","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2165\/11599470-000000000-00000","article-title":"The cost effectiveness of human papillomavirus vaccines: a systematic review","volume":"72","author":"Seto","year":"2012","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127625_bb0100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/cid\/ciw845","article-title":"Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men","volume":"64","author":"Lin","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2025.127625_bb0105","article-title":"Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.vaccine.2025.127625_bb0110","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.vaccine.2023.02.025","article-title":"Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: a modelling-based cost-effectiveness analysis","volume":"41","author":"Wahab","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127625_bb0115","first-page":"242","article-title":"The cost effectiveness and public health impact of gender-neutral quadrivalent human papillomavirus vaccination in Korea","volume":"35","author":"Kim","year":"2020","journal-title":"\ub300\ud55c\ubd80\uc778\uc885\uc591\ud559\ud68c \ud559\uc220\ub300\ud68c\uc9c0"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0120","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1080\/13696998.2023.2282912","article-title":"Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan","volume":"26","author":"Palmer","year":"2023","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.vaccine.2025.127625_bb0125","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/21645515.2016.1140288","article-title":"The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model","volume":"12","author":"Chesson","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2025.127625_bb0130","series-title":"Module on immunisation: Section 6.10 human papillomavirus vaccine","author":"Department of Health, T.G.o.t.H.K.S.A.R","year":"2018"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0135","first-page":"958","article-title":"Community-based surveys for determining the prevalence of HIV, Chlamydia, and gonorrhoea in men having sex with men in Hong Kong","author":"Wong","year":"2013","journal-title":"J Sex Transm Dis [Internet]"},{"key":"10.1016\/j.vaccine.2025.127625_bb0140","first-page":"36","article-title":"Health and economic impact of delaying large-scale HPV vaccination and screening implementation on cervical cancer in China: a modelling study","author":"Gao","year":"2023","journal-title":"Lancet Regional Health\u2013Western Pacific"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127625_bb0145","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/ijc.35242","article-title":"HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: a cost-effectiveness analysis","volume":"156","author":"Liu","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.vaccine.2025.127625_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2023.107743","article-title":"Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: a comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection","volume":"178","author":"Choi","year":"2024","journal-title":"Prev. Med."},{"issue":"5","key":"10.1016\/j.vaccine.2025.127625_bb0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"New England J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127625_bb0160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/pathogens11030314","article-title":"Incidence, persistence, and clearance of anal human papillomavirus among men who have sex with men in China: an observational cohort study","volume":"11","author":"Zhou","year":"2022","journal-title":"Pathogens"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127625_bb0165","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol."},{"issue":"37","key":"10.1016\/j.vaccine.2025.127625_bb0170","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1016\/j.vaccine.2017.07.078","article-title":"Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127625_bb0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00042560-199804010-00005","article-title":"Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors","volume":"17","author":"Palefsky","year":"1998","journal-title":"JAIDS J Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.vaccine.2025.127625_bb0180","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s10096-021-04229-y","article-title":"Human papillomavirus prevalence among men who have sex with men in China: a systematic review and meta-analysis","volume":"40","author":"Zhou","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"9","key":"10.1016\/j.vaccine.2025.127625_bb0185","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/cid\/cir064","article-title":"HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV","volume":"52","author":"de Pokomandy","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2025.127625_bb0190","first-page":"32","article-title":"Cost-effectiveness of screening and treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV","author":"Cheng","year":"2023","journal-title":"Lancet Regional Health\u2013Western Pacific"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127625_bb0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3393\/ac.2013.29.5.182","article-title":"Characteristics and survival of Korean anal cancer from the Korea central cancer registry data","volume":"29","author":"Park","year":"2013","journal-title":"Annals Coloproctol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127625_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25110","article-title":"Evidence of synergistic relationships between HIV and human papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status","volume":"21","author":"Looker","year":"2018","journal-title":"J. Int. AIDS Soc."},{"issue":"51","key":"10.1016\/j.vaccine.2025.127625_bb0205","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.vaccine.2014.10.052","article-title":"Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia","volume":"32","author":"Deshmukh","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127625_bb0210","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciaa166","article-title":"The natural history of anal high-grade squamous intraepithelial lesions in gay and bisexual men","volume":"72","author":"Poynten","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"14","key":"10.1016\/j.vaccine.2025.127625_bb0215","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/QAD.0b013e3283633111","article-title":"Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men","volume":"27","author":"Tong","year":"2013","journal-title":"Aids"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127625_bb0220","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00042560-199804010-00004","article-title":"Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men","volume":"17","author":"Palefsky","year":"1998","journal-title":"JAIDS J Acquired Immune Deficiency Syndromes"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0225","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2352-3018(23)00257-6","article-title":"Survival by sex and HIV status in patients with anal cancer in the USA between 2001 and 2019: a retrospective cohort study","volume":"11","author":"Shing","year":"2024","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127625_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194159","article-title":"Uptake of human papillomavirus (HPV) vaccination in Hong Kong: facilitators and barriers among adolescent girls and their parents","volume":"13","author":"Yuen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127625_bb0235","series-title":"DH to launch catch-up programme for human papillomavirus vaccination (first phase) on December 2","author":"Department of Health, T.G.O.t.H.K.S.A.R","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127625_bb0240","series-title":"Human papillomavirus (HPV) vaccination catch-up programme","author":"Centre for Health Protection, D.o.H., Hong Kong SAR","year":"2024"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127625_bb0245","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.vaccine.2025.127625_bb0250","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","article-title":"Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study","volume":"10","author":"Romanowski","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"19","key":"10.1016\/j.vaccine.2025.127625_bb0255","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.vaccine.2025.127625_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1118-3","article-title":"Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis","volume":"16","author":"Choi","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.vaccine.2025.127625_bb0265","author":"HPV Vaccine in Hong Kong: How Common is HPV Infection?"},{"key":"10.1016\/j.vaccine.2025.127625_bb0270","series-title":"USD to HKD Exchange Rate History for 2023","author":"Exchange-Rates.org","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127625_bb0275","series-title":"The 2024\u201325 budget","author":"Chan","year":"2024"},{"issue":"30","key":"10.1016\/j.vaccine.2025.127625_bb0280","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1016\/j.vaccine.2020.05.031","article-title":"Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands","volume":"38","author":"Simons","year":"2020","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127625_bb0285","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.vaccine.2017.04.050","article-title":"Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: a systematic review","volume":"35","author":"Wong","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127625_bb0290","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2016007","article-title":"Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States","volume":"18","author":"Meites","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.vaccine.2025.127625_bb0295","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/QAI.0000000000003057","article-title":"Prevalence and risk factors of anal HPV infection in MSM living with HIV: identifying the target groups to prioritize for immunization","volume":"91","author":"Bruzzesi","year":"2022","journal-title":"JAIDS J Acquired Immune Deficiency Syndromes"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127625_bb0300","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.8.1800055","article-title":"Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to march 2017","volume":"24","author":"Edelstein","year":"2019","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2025.127625_bb0305","series-title":"Human papilloma virus vaccine","author":"Gallego","year":"2024"},{"issue":"10108","key":"10.1016\/j.vaccine.2025.127625_bb0310","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127625_bb0315","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg. Infect. Dis."},{"issue":"11","key":"10.1016\/j.vaccine.2025.127625_bb0320","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/vaccines9111218","article-title":"Effectiveness of a community-based organization\u2014private clinic service model in promoting human papillomavirus vaccination among Chinese men who have sex with men","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T03:52:53Z","timestamp":1765857173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":64,"alternative-id":["S0264410X25009223"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127625","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.06.02.25328835","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127625"}}